SWAV * Stock Overview A medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Shockwave Medical, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Shockwave Medical Historical stock prices Current Share Price US$3,700.00 52 Week High US$5,111.53 52 Week Low US$3,700.00 Beta 1.01 1 Month Change 0% 3 Month Change n/a 1 Year Change -23.40% 3 Year Change n/a 5 Year Change n/a Change since IPO -16.56%
Recent News & Updates
Shockwave Medical Unveils First Clinical Outcomes of New IVL Platform in Late-Breaking Presentation at VIVA 2024 Nov 05
Shockwave Medical, Inc. Announces U.S. Launch of the Shockwave E8 Peripheral Ivl Catheter Sep 16
Shockwave Medical Files Form 15 Jun 13 Shockwave's Common Stock Ceases Trading on NASDAQ Jun 05
Shockwave Medical, Inc. Announces Termination of Employment of Renee Gaeta as Chief Financial Officer Johnson & Johnson (NYSE:JNJ) completed the acquisition of Shockwave Medical, Inc. (NasdaqGS:SWAV) from a group of sellers. Jun 01
See more updates
Shockwave Medical Unveils First Clinical Outcomes of New IVL Platform in Late-Breaking Presentation at VIVA 2024 Nov 05
Shockwave Medical, Inc. Announces U.S. Launch of the Shockwave E8 Peripheral Ivl Catheter Sep 16
Shockwave Medical Files Form 15 Jun 13 Shockwave's Common Stock Ceases Trading on NASDAQ Jun 05
Shockwave Medical, Inc. Announces Termination of Employment of Renee Gaeta as Chief Financial Officer Johnson & Johnson (NYSE:JNJ) completed the acquisition of Shockwave Medical, Inc. (NasdaqGS:SWAV) from a group of sellers. Jun 01
Shockwave Medical Withdraws Earnings Guidance for the Full Year 2024 May 08
Shockwave Medical, Inc., Annual General Meeting, May 29, 2024 May 01
Shockwave Medical, Inc. Announces Investigators Presented Six-Month Data from the Full Population of the Reducer-I Study Apr 09 Johnson & Johnson (NYSE:JNJ) entered into a definitive agreement to acquire Shockwave Medical, Inc. (NasdaqGS:SWAV) for $13 billion. Apr 06
Johnson & Johnson Reportedly Considers Deal for Shockwave Medical Mar 28
Shockwave Medical, Inc. Provides Earnings Guidance for 2024 Feb 16
Shockwave Medical, Inc. Appoints Renee Gaeta as Chief Financial Officer, Effective February 5, 2024 Jan 29 Shockwave Medical, Inc. to Report Q4, 2023 Results on Feb 15, 2024
Shockwave Medical, Inc. Announces New Data Demonstrating One-Year Outcomes with Coronary Lithotripsy Nov 10
Shockwave Medical, Inc. Provides Revenue Guidance for the Full Year 2023 Nov 08
Shockwave Medical, Inc. Introduces Enhanced Coronary IVL Catheter in the United States Oct 23
Shockwave Medical, Inc. Announces New Shockwave Coronary IVL Publications Confirm Safety and Efficacy Across Multiple Calcium Morphologies Oct 20
Shockwave Medical, Inc. Appoints Nick West as Associate Chief Medical Officer Sep 14
Daniel K. Puckett Notifies Shockwave Medical, Inc. of His Intention to Retire as Chief Financial Officer Sep 13
Daniel K. Puckett Notifies Shockwave Medical, Inc. of His Intention to Retire as Chief Financial Officer Sep 12
Shockwave Medical, Inc. Revises Revenue Guidance for the Full Year 2023 Aug 09
Shockwave Medical, Inc.(NasdaqGS:SWAV) dropped from Russell 2000 Dynamic Index Jun 25
Shockwave Medical, Inc. Appoints Kevin Ballinger to Board of Directors and Will Serve on Shockwave’s Nominating and ESG Committee and the Compensation Committee of the Board May 18 Shockwave Medical Reportedly Picks Up Takeover Interest from Two Additional Suitors May 13
Shockwave Medical Reportedly Picks Up Takeover Interest from Two Additional Suitors May 12
Shockwave Medical, Inc. Revises Revenue Guidance for the Year 2023 May 09
Shockwave Medical, Inc. Provides Earnings Guidance for the Full Year 2023 Feb 18
ShockWave Medical, Inc. (NasdaqGS:SWAV) entered into a definitive agreement to acquire Neovasc Inc. (TSX:NVCN) from Strul Medical Group LLC and others for $75.04 million. Jan 19
ShockWave Medical, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2022 and Fiscal Year 2023 Jan 18 ShockWave Medical, Inc. to Report Q4, 2022 Results on Feb 16, 2023 ShockWave Medical, Inc. Revises Revenue Guidance for the Year 2022 Nov 08
ShockWave Medical, Inc. Confirms Consistent Outcomes for IVL in the larger Prospective “Real World” Study of Patients with Heavily Calcified Peripheral Arterial Disease Nov 03
Chief Accounting Officer recently sold Mex$22m worth of stock Aug 31
ShockWave Medical, Inc. Revises Revenue Guidance for the Full Year 2022 Aug 09
Shockwave Medical, Inc. and Genesis MedTech Group Successfully Obtains Approval from China’S National Medical Products Administration to Market and Sell the Shockwave IVL System with the Shockwave C2 Coronary IVL Catheters and the Shockwave M5 and S4 Peripheral IVL Catheters in China May 24 Shockwave Ivl Maintains Superiority to Angioplasty in Calcified Peripheral Disease At Two Years ShockWave Medical, Inc. Revised Earnings Guidance for the Full Year 2022 May 10
ShockWave Medical, Inc., Annual General Meeting, Jun 23, 2022 May 02
Independent Director recently sold Mex$7.9m worth of stock Apr 02
Shockwave Medical, Inc. Announces the Global Commercial Availability of the Shockwave M5+ Peripheral IVL Catheter After Receiving Both CE Mark and U.S. Food and Drug Administration Clearance Apr 01
Shockwave Medical Announces Japanese Regulatory Approval of Coronary IVL Mar 31
Key Executive recently sold Mex$17m worth of stock Mar 02
Key Executive recently sold Mex$17m worth of stock Feb 26
ShockWave Medical, Inc. Announces Executive Changes Feb 24
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Feb 19
ShockWave Medical, Inc. Provides Revenue Guidance for the Full Year 2022 Feb 18
ShockWave Medical, Inc. Enrolls First Patient in Disrupt BTK II Study for Long, Calcified, Below the Knee Lesions Nov 24 Shareholder Returns SWAV * MX Medical Equipment MX Market 7D 0% 0% 0% 1Y -23.4% 0% 0%
See full shareholder returns
Return vs Market: SWAV * underperformed the MX Market which returned 3.7% over the past year.
Price Volatility Is SWAV *'s price volatile compared to industry and market? SWAV * volatility SWAV * Average Weekly Movement n/a Medical Equipment Industry Average Movement 0% Market Average Movement 0% 10% most volatile stocks in MX Market 0% 10% least volatile stocks in MX Market 0%
Stable Share Price: SWAV * has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine SWAV *'s volatility change over the past year.
About the Company ShockWave Medical, Inc., a medical device company, develops intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters for use in our IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter for use in IVL System in large diameter vessels. It also provides product for the treatment of coronary artery disease, such as C2 IVL catheter and C2+IVL catheter that are two-emitter catheters for use in IVL system.
Show more Shockwave Medical, Inc. Fundamentals Summary How do Shockwave Medical's earnings and revenue compare to its market cap? SWAV * fundamental statistics Market cap Mex$110.74b Earnings (TTM ) Mex$4.17b Revenue (TTM ) Mex$11.49b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) SWAV * income statement (TTM ) Revenue US$671.28m Cost of Revenue US$87.57m Gross Profit US$583.70m Other Expenses US$339.82m Earnings US$243.88m
Last Reported Earnings
Sep 30, 2023
Earnings per share (EPS) 6.61 Gross Margin 86.95% Net Profit Margin 36.33% Debt/Equity Ratio 121.6%
How did SWAV * perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2023/11/25 23:25 End of Day Share Price 2023/08/28 00:00 Earnings 2023/09/30 Annual Earnings 2022/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Shockwave Medical, Inc. is covered by 12 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Travis Steed BofA Global Research William Plovanic Canaccord Genuity Kristen Stewart CL King & Associates, Inc.
Show 9 more analysts 